On June 9 at 20:00, 36Kr hosted an online event called the "Keep up the Miracle" X·36Under36 Entrepreneur Event. At this insightful and long-term venture capital ecological event, 36Kr unveiled "X·36Under36" -the list of S-class entrepreneurs of the Year 2022.
"X·36Under36" is a list of S-rated entrepreneurs in the top 10 hottest startup fields of the year. This list is generated and filtered by the knowledge partner team of top investors from more than 1,000 high-quality projects in the past six months.
36Kr started its 36under36 "Great Investors/Entrepreneurs" program in 2017. This year, unlike any other, a representative group of 360 entrepreneurs, with an average age of 31, was included as the inaugural members in order to find potential great entrepreneurs on a wider scale. 36KR will use a longer time dimension to track the business fortunes of entrepreneurs, reach out to the most innovative people in China in a more timely and deep way. To ensure that they remain vigorous in Chinese business in the next decade, and continue to observe how they continue to perform miracles in the modern era; In addition, we will continue to create online special programs focusing on entrepreneurs and investors, including investors chat program ‘Miracle 1V1’, entrepreneur interview program ‘Seed of Miracles’, investors interview program ‘Miracle Talent’, etc.
Dr. Lai Caida, Founder and CEO of METiS Pharmaceuticals, was dubbed as an S-rate entrepreneur in the healthcare sector.
Dr. Lai is a PhD holder of Novartis Pharma and MIT Manufacturing Research Center, where he focuses on dynamic modeling, process optimization and drug crystallization. During his PhD, he founded AquaFresco, a water purification technology startup, which successfully developed and commercialized an innovative wastewater recycling technology and bagged several awards, including MassChallenge, to bring wastewater recycling back to the home. In addition, Dr. Lai worked as a strategy consultant at McKinsey, a top consulting firm, helping top 500 pharmaceutical companies develop digital strategies. As a groundbreaker in AI-driven drug development, Dr. Lai interweaved pharmaceutical formulations, delivery technology and machine learning to lay the foundation for the pharmaceutical technology platform. At the same time, harnessing years of entrepreneurial experience and digital strategy, brought the booming development of METiS.
As the world's first AI-driven drug delivery and drug discovery biotechnology company, METiS has integrated AI, quantum simulation and interdisciplinary technologies, such as high-throughput experimental platform. METiS has set up special AiLNP, AiRNA, AiTEM core technology platform, to predict physical and chemical, biological properties of small molecules and nucleic acid-based drug under the specific environment. METiS‘s Ai-driven dry and wet experiment iteration has achieved more effective and innovative delivery material design, nucleic acid sequence design &optimization, moreover, it enables more advantageous formulation or nucleic acid delivery system design.
We believe that under the leadership of Dr. Lai Caida and the other two co-founders Dr. Wang Wenshou and Dr. Chen Hongmin, METiS will keep up its original aspiration, focusing on drug delivery and drug discovery, empowering the entire pharmaceutical ecosystem. Embracing the lovely future, we believe that miracles continue to happen.
